---
title: "Pfizer, Astellas Padcev combo shows overall survival benefit in urothelial cancer"
date: "2025-02-11 01:24:37"
summary: "A combination of Pfizer (NYSE:PFE) and Astellas' (OTCPK:ALPMF)(OTCPK:ALPMY) antibody-drug conjugate Padcev (enfortumab vedotin-ejfv) with Merck's (MRK) Keytruda (pembrolizumab) demonstrated a sustained overall survival and progression-free survival benefit as a first-line therapy for urothelial cancer. Data showed that Padcev + Keytruda reduced the risk of death by 49% versus chemotherapy. Median..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1467893023/image_1467893023.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* A combination of Pfizer (NYSE:[PFE](https://seekingalpha.com/symbol/PFE "Pfizer Inc.")) and Astellas' ([OTCPK:ALPMF](https://seekingalpha.com/symbol/ALPMF "Astellas Pharma Inc."))([OTCPK:ALPMY](https://seekingalpha.com/symbol/ALPMY "Astellas Pharma Inc.")) antibody-drug conjugate Padcev (enfortumab vedotin-ejfv) with Merck's ([MRK](https://seekingalpha.com/symbol/MRK "Merck & Co., Inc.")) Keytruda (pembrolizumab) demonstrated a sustained overall survival and progression-free survival benefit as a first-line therapy for urothelial cancer.
* Data showed that Padcev + Keytruda reduced the risk of death by 49% versus chemotherapy. Median OS was 33.8 months for the combo compared to 15.9 months for chemotherapy.
* The combo [also reduced](https://seekingalpha.com/pr/19997376-pfizer-and-astellas-padcev-enfortumab-vedotin-ejfv-plus-keytruda-pembrolizumab-shows-long "also reduced") the risk of disease progression or death by 52% versus chemo and median PFS was 12.5 months for the combination compared to 6.3 months for chemo.
* At nearly 30 months of follow-up, the combination doubled median OS and PFS compared to chemo.

[seekalpha](https://seekingalpha.com/news/4405859-pfizer-astellas-padcev-combo-shows-overall-survival-benefit-urothelial-cancer)
